Saturday 17 October 2026
Export SION’s income statement to Excel — free account
Sionna Therapeutics, Inc.
SION Healthcare Biotechnology
In the quarter to June 2026, EPS fell 61.0% and free cash flow fell 22.4%, each against the same quarter a year earlier.
3.89
0.19
−4.66%
Follow SION
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 7.26 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 45.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 35 | 41 | 59 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (47) | (62) | (75) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (47) | (62) | (75) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | (2) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (16.11) | (15.99) | (1.88) | |||||
| Cash flow | — | — | — | — | — | — | — | (14.90) | (13.68) | (1.66) | |||||
| Capex | — | — | — | — | — | — | — | (0.38) | (0.01) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | — | (15.28) | (13.69) | (1.67) | |||||
| Book value | — | — | — | — | — | — | — | (39.17) | (42.42) | 7.68 | |||||
| Shares, m | — | — | — | — | — | — | — | 3 | 4 | 40 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (44) | (53) | (66) | ||||
| Capex | — | — | — | — | — | — | — | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (45) | (53) | (67) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 31 | 141 | 230 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (39) | (148) | (236) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (115) | (164) | 307 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (51.90) | (29.42) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (78.38) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 44.29 | (105.18) | |||||
Negative figures in brackets.
Charts ten years each
Sionna Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA | $190.2M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| STRO Sutro Biopharma, Inc. | $190.0M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| YARW Yarrow Bioscience, Inc | $188.8M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| TRDA Entrada Therapeutics, Inc. | $186.1M | — (loss-making) | — (loss-making) | −53.95% (below 0%: shrinking) | n/m | −9.10% (below 0%: shrinking) | 100.00% | (5,007.02%) | Compare |
| UPB Upstream Bio, Inc. | $184.6M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| SION Sionna Therapeutics, Inc. | $184.5M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | |
| ELDN Eledon Pharmaceuticals, Inc. | $184.5M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACOG Alpha Cognition Inc. | $184.0M | — (loss-making) | — | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $181.4M | — (loss-making) | — (loss-making) | −78.46% (below 0%: shrinking) | n/m | +31.95% (above 0%: growing) | 100.00% | (8,673.93%) | Compare |
| Median of peers | $185.4M | — | — | −17.50% | — | +11.94% | 100.00% | (1,750.85%) |
Sionna Therapeutics, Inc. (SION) key facts
- Sionna Therapeutics, Inc. (SION) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SION traded at $3.89, a market capitalization of $184.5 million.
- Return on equity was −105.2% and debt-to-equity 0.00.